News

CLINUVEL
Posted by CLINUVEL
August 24, 2016

Appendix 4E - Preliminary Final Report 2015/16

24 August 2016 Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY)...

Read More
CLINUVEL
Posted by CLINUVEL
August 22, 2016

Lapse and Forfeit of Unlisted Conditional Performance Rights

23 August 2016 CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY)...

Read More
CLINUVEL
Posted by CLINUVEL
August 14, 2016

CLINUVEL Newsletter - August 2016

16 August 2016 In the arduous journey from explorative concept to development...

Read More
CLINUVEL
Posted by CLINUVEL
August 9, 2016

Notice of Initial Substantial Holder

10 August 2016 Enclosed are the details of a notice of initial...

Read More
CLINUVEL
Posted by CLINUVEL
August 3, 2016

Appendix 3Y

03 August 2016 We (the entity) give ASX the following information under...

Read More
CLINUVEL
Posted by CLINUVEL
August 2, 2016

Appendix 3B

02 August 2016 New issue announcement, application for quotation of additional securities...

Read More
CLINUVEL
Posted by CLINUVEL
August 2, 2016

CLINUVEL completes pre-clinical study of SCENESSE® as combination therapy

02 August 2016 CLINUVEL prepares New Drug Application (NDA) for the treatment...

Read More
CLINUVEL
Posted by CLINUVEL
July 28, 2016

Appendix 4C - Q4 FY16

28 July 2016 Enclosed is a copy of the quarterly report for...

Read More
CLINUVEL
Posted by CLINUVEL
July 17, 2016

FDA accepts SCENESSE® clinical data package for NDA submission

17 July 2016 Clinuvel prepares New Drug Application (NDA) for the treatment...

Read More
CLINUVEL
Posted by CLINUVEL
July 5, 2016

FDA awards SCENESSE® Fast Track designation for treatment of EPP

05 July 2016 Executive summary: FDA awards Fast Track Designation¹ to expedite...

Read More